Moderna Exceeds Revenue Estimates with Strong International COVID Vaccine Sales
Moderna exceeded first-quarter revenue estimates, driven by robust international sales of its COVID-19 vaccine. International revenue reached $311 million, compared to $78 million in the U.S., with the company expecting a more stable U.S. market in 2026. Shares rose nearly 8% in premarket trading.
Topics: COVID-19 vaccine earnings report international sales Moderna revenue stock price movement